Company news

Ultragenyx Pharmaceutical Inc. news in 2022

Ultragenyx Pharmaceutical Inc.'s news releases, calls and decks from 2022, newest first.

View company

Ultragenyx to Present at Piper Sandler Healthcare Conference

November 21, 2022

Ultragenyx Announces Departure of Chief Financial Officer

November 9, 2022

Ultragenyx to Present at Upcoming Healthcare Conferences

November 8, 2022

Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update

November 1, 2022

Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update

October 26, 2022

Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR

September 8, 2022

Ultragenyx to Participate at Citi BioPharma Conference

August 31, 2022

Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update

July 27, 2022

Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corporate Update

July 24, 2022

Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study

July 17, 2022

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets

July 13, 2022

Ultragenyx to Present at Goldman Sachs Global Healthcare Conference

June 9, 2022

Ultragenyx to Present at Jefferies Global Healthcare Conference

May 31, 2022

Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Therapy Studies at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

May 18, 2022

Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics

May 16, 2022

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

May 8, 2022

Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update

May 4, 2022

Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference

May 2, 2022

Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update

April 26, 2022

Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report

April 24, 2022

Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

April 21, 2022

Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta

April 19, 2022

Ultragenyx to Participate in the Cowen Health Care Conference

March 1, 2022

Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

February 9, 2022

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2021 Financial Results and Corporate Update

February 2, 2022

Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvita® in Ultragenyx Territories* And Dojolvi® Globally; Provides Pipeline Updates and 2022 Milestones

January 9, 2022

Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference

January 5, 2022

GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome

January 4, 2022

Ultragenyx to Present at 40th Annual JP Morgan Healthcare Conference

January 2, 2022

Calls in 2022

Decks in 2022